How AI, Analytics, and Collaboration Can Solve Specialty Drug Spending Challenges
Nicole Bulochnik, Abarca Senior Vice President of Drug Value Strategy, explained how AI, analytics, and cross-sector collaboration can transform specialty drug costs.
presented by
presented by
Are GLP-1 Drugs Here to Stay?
We recently spoke with Nicole Bulochnik, senior vice president of drug strategy for Abarca, about what payers need to consider as demand for this group of weight-loss drugs remains high.
Solving Healthcare’s Provider Data Problem Starts with Interoperability
Break down the silos. Take control of your provider data.
presented by
How AI and Machine Learning Can Transform Pharmacy Benefits Management
Abarca executives see plenty of potential for new technologies but note the need to strike the right balance between tech and human intervention.
presented by
Unlocking Transparency in PBM Pricing
Dan Reedy, senior director of pricing and underwriting for Abarca, spoke recently with MedCity News about what payers should consider as they explore new models and press for greater transparency.
presented by
The PBM Model of the Future: Why Payers Are Unbundling PBM Services
Javier Gonzalez, Chief Growth and Commercial Officer at Abarca, about why payers are increasingly looking for alternatives to the traditional PBM model.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
presented by
The 5 Best Medical Billing Outsourcing Companies
Medical billing is a tedious administrative task, but outsourcing it may be the key to increased revenue. Explore the top medical billing outsourcing companies and the benefits of partnering with one.
presented by
What Do Payers Need to Help Value-Based Contracting Deals for Novel Therapies Succeed?
A panel discussion at the annual Abarca Forward conference in Puerto Rico last month sought to identify some of the innovative financial approaches that can be applied to managing the high price of novel therapies. Conversations also addressed what payers need for these financing models to be sustainable.